▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / BMY

BMY — BRISTOL MYERS SQUIBB CO

—
NYSE · Health Care · Pharmaceuticals · CIK 14272 ·
Last close
$55.53
Market Cap
$113.40B
52W High
$61.59
52W Low
$53.44
ADV30
11,659,127
Next earnings
2026-07-30
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 11,489,000,000 8,068,000,000 3,365,000,000 2,677,000,000 86,476,000,000 9,574,000,000 66,374,000,000
Dec 2025 12,503,000,000 8,406,000,000 2,813,000,000 1,087,000,000 90,038,000,000 10,209,000,000 71,532,000,000
Sep 2025 12,222,000,000 8,787,000,000 3,639,000,000 2,201,000,000 96,889,000,000 15,726,000,000 78,289,000,000
Jun 2025 12,269,000,000 8,897,000,000 3,774,000,000 1,310,000,000 94,676,000,000 12,599,000,000 77,187,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$13,306,000,000
Investing CF
$-3,764,000,000
Financing CF
$-10,915,000,000
CapEx
$-1,398,000,000
Dividends Paid
$-5,070,000,000
Buybacks
$0
EPS Diluted TTM
$3.56
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$18,287,000,000
Inventory
$2,756,000,000
Receivables
$12,083,000,000
ST Investments
$912,000,000
EBIT TTM
$11,405,000,000
Pretax Income TTM
$9,597,000,000
Interest Exp TTM
$1,808,000,000
Analysts
25

Yahoo Snapshot (yfinance, live)

Total Revenue
$48,482,000,896
EBITDA
$18,973,999,104
Free Cash Flow
$9,851,750,400
Enterprise Value
$149,373,222,912
Total Cash
$10,485,999,616
Total Debt
$46,428,999,680
Shares Out
2,042,071,247
Trailing EPS
$3.57
Book Value
$9.83
ROE
38.7%
ROA
10.7%
Div Yield
4.54%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 48,195,000,000 13,724,000,000 7,054,000,000 90,038,000,000 71,532,000,000 — 14,156,000,000
Dec 2024 48,300,000,000 5,887,000,000 -8,948,000,000 92,603,000,000 76,215,000,000 — 15,190,000,000
Dec 2023 45,006,000,000 8,195,000,000 8,025,000,000 95,159,000,000 65,674,000,000 — 13,860,000,000
Dec 2022 46,159,000,000 9,104,000,000 6,327,000,000 96,820,000,000 65,702,000,000 — 13,066,000,000

TTM Snapshot

Revenues TTM
$45,700,000,000
NetIncome TTM
$6,291,000,000
OpCashFlow TTM
$0
Assets (Latest)
$92,603,000,000
Forward EPS
$6.17

Max Pain — expiry 2026-06-26

max pain strike: $55.00 · spot: $55.36 · call oi: 12,538 · put oi: 10,053
Expected Move to 2026-06-26: ±$1.08 (1.95%) — implied range $54.28 – $56.44 · ATM straddle on $55.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VRTX VERTEX PHARMACEUTICALS INC / MA $118.89B $468.42 —
GSK GSK plc $104.31B $52.07 —
GLAXF GSK plc $102.97B $25.70 —
SNYNF Sanofi $99.81B $83.39 —
SNY Sanofi $99.58B $41.60 —

News headlines (Yahoo Finance, 1h cache)

64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
2026-06-24 14:02 · Yahoo
Does Bristol Myers Squibb’s 2026 Dividend and Pipeline Ambition Reframe Its Capital Priorities (BMY)?
2026-06-24 02:09 · Yahoo
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
2026-06-23 21:45 · Yahoo
The $50B Plan Merck Stock Was Broadcasting
2026-06-23 19:57 · Yahoo
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies
2026-06-23 19:37 · Yahoo
Should You Buy Or Sell AbbVie Stock At $230?
2026-06-23 12:20 · Yahoo
How Kardigan spun deal leftovers into a $400M IPO
2026-06-23 10:21 · Yahoo
3 Reasons to Buy Bristol Myers Squibb Stock
2026-06-22 19:13 · Yahoo
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
2026-06-22 17:00 · Yahoo
Merck Stock’s New Drugs Were Already Answering The Big Question
2026-06-22 14:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →